Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Clin Cancer Res. 2017 Oct 23;24(1):62–72. doi: 10.1158/1078-0432.CCR-17-0357

Figure 3.

Figure 3

Clinical trial patient TIL were collected pre- and post-treatment regimen and monocytic populations analyzed using flow cytometry. (A) Summary data of percentage of CD14+HLA-DRhiCD68+ and CD14+CD33+HLA-DRlow monocytes pre- and post-treatment are shown (n=9). (B) Summary data of CD80 and CD16 expression pre- and post-treatment on CD141+ DC and (C) CD1c+ DC are shown (n= 9). Significance was calculated with paired t test, *p<0.05.